12月31日，生物股份涨1%，截至发稿，报15.15元/股，成交2.23亿元，换手率1.34%，总市值168.43亿 元。 资料显示，金宇生物技术股份有限公司位于内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金 宇大街1号，成立日期1993年3月13日，上市日期1999年1月15日，公司主营业务涉及主要从事兽用生物 制品的研发、生产与销售。主营业务收入构成为：生物制药94.42%，其他收入3.18%，其他(补 充)2.40%。 截至发稿，刘重杰累计任职时间7年243天，现任基金资产总规模328.73亿元，任职期间最佳基金回报 102.09%， 任职期间最差基金回报-36.57%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，招商基金旗下1只基金重仓生物股份。招商中证畜牧养殖ETF（516670）三季度增持83.4万 股，持有股数360.29万股，占基金净值比例为3.95%，位居第八大重仓股。根据测算，今日浮盈赚取 ...

12月30日，生物股份盘中下跌2.01%，截至09:54，报15.08元/股，成交8377.86万元，换手率0.50%，总 市值167.65亿元。 资料显示，金宇生物技术股份有限公司位于内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金 宇大街1号，成立日期1993年3月13日，上市日期1999年1月15日，公司主营业务涉及主要从事兽用生物 制品的研发、生产与销售。主营业务收入构成为：生物制药94.42%，其他收入3.18%，其他(补 充)2.40%。 生物股份所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：生物安全、MSCI 中国、增持回购、融资融券、中盘等。 截至9月30日，生物股份股东户数4.90万，较上期减少10.70%；人均流通股22673股，较上期增加 11.12%。2025年1月-9月，生物股份实现营业收入10.42亿元，同比增长7.38%；归母净利润1.61亿元，同 比减少4.85%。 机构持仓方面，截止2025年9月30日，生物股份十大流通股东中，国泰中证畜牧养殖ETF（159865）位 居第四大流通股东，持股2503.98万股，相比上期增加908.97万股。香港中央结 ...

12月24日，生物股份跌6.39%，截至发稿，报15.82元/股，成交2.10亿元，换手率1.15%，总市值175.88 亿元。 资料显示，金宇生物技术股份有限公司位于内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金 宇大街1号，成立日期1993年3月13日，上市日期1999年1月15日，公司主营业务涉及主要从事兽用生物 制品的研发、生产与销售。主营业务收入构成为：生物制药94.42%，其他收入3.18%，其他(补 充)2.40%。 从基金十大重仓股角度 数据显示，易方达基金旗下1只基金重仓生物股份。易方达中证现代农业主题ETF（562900）三季度增 持1.96万股，持有股数23.91万股，占基金净值比例为2.79%，位居第八大重仓股。根据测算，今日浮亏 损失约25.82万元。 易方达中证现代农业主题ETF（562900）成立日期2021年12月2日，最新规模8262.09万。今年以来收益 11.18%，同类排名3366/4197；近一年收益10.72%，同类排名3368/4157；成立以来亏损19.95%。 易方达中证现代农业主题ETF（562900）基金经理为宋钊贤、聂启文。 截至发稿，宋钊贤累计任 ...

每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ 每经AI快讯，瑞普生物（SZ 300119，收盘价：19.18元）12月15日晚间发布公告称，公司第六届2025年 第六次董事会临时会议于2025年12月15日在公司会议室以现场会议方式召开。会议审议了《关于选举第 六届董事会董事长的议案》等文件。 2024年1至12月份，瑞普生物的营业收入构成为：兽用生物制品占比43.12%，兽用药物占比33.86%，宠 物供应链占比20.63%，其他占比2.38%。 截至发稿，瑞普生物市值为89亿元。 （记者 王晓波） ...

Core Viewpoint - Reap Bio announced the convening of its fifth board meeting to discuss amendments to the company's articles of association, indicating ongoing governance and strategic adjustments [1] Company Summary - Reap Bio's revenue composition for the year 2024 is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1] - As of the report, Reap Bio has a market capitalization of 9.2 billion yuan [1]

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant growth this year, with an 81.11% increase in share price, indicating strong market performance and investor interest [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - The company has distributed a total of 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average circulating shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional shareholders include Guotai Zhongxin Livestock Breeding ETF, which holds 25.0398 million shares, and Hong Kong Central Clearing Limited, holding 21.1968 million shares, both showing increases in their holdings [3].

Company Overview - KQ Bio, established on January 11, 2001, and listed on September 22, 2020, is located in Wuhan, Hubei Province. The company specializes in the research, production, and sales of veterinary biological products and animal epidemic prevention technology services [1][2]. - The main business revenue composition includes 94.64% from veterinary biological products, 4.46% from other sources, and 0.90% from supplementary services [1]. Financial Performance - For the period from January to September 2025, KQ Bio achieved a revenue of 738 million yuan, representing a year-on-year growth of 10.87%. The net profit attributable to the parent company was 338 million yuan, showing a year-on-year increase of 29.62% [2]. - Cumulative cash dividends since the A-share listing amount to 711 million yuan, with 488 million yuan distributed over the past three years [3]. Stock Performance - As of November 17, KQ Bio's stock price was 16.24 yuan per share, with a market capitalization of 7.57 billion yuan. The stock has increased by 17.15% year-to-date but has seen a decline of 0.43% over the last five trading days, 6.13% over the last 20 days, and 5.80% over the last 60 days [1]. - The number of shareholders as of September 30 was 9,713, an increase of 2.41% from the previous period, while the average circulating shares per person decreased by 2.36% to 47,990 shares [2]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 5.5731 million shares, an increase of 3.2155 million shares from the previous period [3].

Summary of JinKang Biological Conference Call Company Overview - JinKang Biological is a comprehensive agricultural enterprise involved in oil processing, corn procurement, pig farming, feed production, and veterinary biological products [2][3] - Established in 2000, the company has over 50 large-scale breeding bases across China and ranks among the top 20 in the domestic pig farming industry [3] Key Financial Metrics - In 2024, JinKang is expected to have a pig output of 3.03 million heads, with feed sales of 2.83 million tons and veterinary business revenue of 990 million yuan [2] - The gross profit contributions for 2024 are as follows: - Pig farming: 900 million yuan (46%) - Feed business: 580 million yuan (30%) - Veterinary business: 620 million yuan (24%) [2][5] - The company reported a net loss of 1.363 billion yuan in 2023 due to pig price fluctuations, but performance is expected to improve in 2024 [2][5] - The projected net profit for 2024 is approximately 600 million yuan, with an expected decrease to 500 million yuan in 2025 [4][9] Industry Context - The industry is currently at the bottom of the cycle, expected to last until mid-2026, with a recovery anticipated in the second half of 2026 [2][8] - The duration of industry losses and the degree of capacity reduction are key indicators for recovery [8] Competitive Advantages - JinKang Biological has three core competitive advantages: 1. Integrated operational model leading to stable performance and a lighter asset-liability structure [6][7] 2. Geographic advantages with production concentrated in Xinjiang, Gansu, and Henan, providing low-density farming environments and biosecurity [7] 3. Strong cost control, with total comprehensive costs expected to decrease from 15 yuan per kg to 13.5 yuan by the end of 2024, and further to 12 yuan by Q3 2025 [7] Valuation and Investment Potential - The current price-to-earnings (P/E) ratio is approximately 17, significantly lower than the industry average of 33, indicating potential for value investment [4][9] - Factors supporting investment in JinKang include the upcoming industry recovery, stable operational model, core competitive advantages, and undervalued market position [9]

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant price movements, with a year-to-date increase of 58.86% and a recent trading volume indicating active market participation [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average number of tradable shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional holdings include the Guotai Zhongzheng Livestock Breeding ETF, which is the fourth-largest shareholder with 25.0398 million shares, an increase of 9.0897 million shares from the previous period [3].

Core Viewpoint - 科前生物 is a leading company in the veterinary biological products sector in China, focusing on animal vaccine research and development, with strong financial performance and growth potential in the coming years [1][2][5]. Financial Performance - In Q3 2025, 科前生物 reported revenue of 738 million yuan, ranking 8th in the industry, with the top competitor 中牧股份 generating 4.442 billion yuan [2]. - The net profit for the same period was 337 million yuan, placing the company 2nd in the industry, with 瑞普生物 leading at 391 million yuan [2]. - The company's main business, veterinary biological products, accounted for 94.64% of total revenue, while other segments contributed 4.46% [2]. Profitability and Debt Management - As of Q3 2025, 科前生物's asset-liability ratio was 12.21%, lower than the previous year's 12.94% and significantly below the industry average of 28.36%, indicating strong debt repayment capability [3]. - The gross profit margin was 66.96%, an increase from 64.01% year-on-year and higher than the industry average of 40.13%, reflecting robust profitability [3]. Management and Shareholder Information - The chairman, 陈慕琳, received a salary of 1.6389 million yuan in 2024, up from 1.591 million yuan in 2023, an increase of 47,900 yuan [4]. - As of September 30, 2025, the number of A-share shareholders increased by 2.41% to 9,713, while the average number of shares held per shareholder decreased by 2.36% [5]. Growth Prospects - The company has been actively engaged in new product development, obtaining four new veterinary drug registration certificates in the first half of 2025, including a new inactivated vaccine for pigs [5][6]. - Forecasts suggest that 科前生物's revenue will grow to 1.038 billion yuan in 2025, 1.200 billion yuan in 2026, and 1.395 billion yuan in 2027, with net profits projected at 428 million yuan, 519 million yuan, and 610 million yuan respectively [5][6].